REBLOZYL (luspatercept-aamt)
ANEMIA IN BETA THALASSEMIA·+3
CELGENE
Indication
Anemia in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis
Anemia in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) is a hematologic complication of a rare, clonal myeloid overlap malignancy affecting hematopoietic stem cells, most frequently diagnosed in older adults. Read more about Anemia in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis
2 drugs 2 manufacturers
Drugs that treat it
Common Anemia in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis therapies.
REBLOZYL (luspatercept-aamt)
ERYTHROID (RBC) MATURATION AGENTS·ANEMIA IN BETA THALASSEMIA·+3
CELGENE/BMS
Filter & compare in the drug finder →Opens the drug finder with Anemia in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonAbout Anemia in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis.
Anemia in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) is a hematologic complication of a rare, clonal myeloid overlap malignancy affecting hematopoietic stem cells, most frequently diagnosed in older adults.
It arises from ineffective erythropoiesis combined with dysplastic bone marrow proliferation.
Defining clinical and pathophysiologic features include sustained peripheral thrombocytosis alongside dyserythropoiesis characterized by pathologic iron accumulation, where ring sideroblasts constitute at least 15% of erythroid precursors (or at least 5% in the presence of an SF3B1 mutation).
The disease course is commonly driven by molecular alterations combining spliceosome mutations, notably SF3B1, with myeloproliferative driver mutations such as JAK2 V617F, CALR, or MPL.
- nih.gov
Anemia in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) is a hematologic complication of a rare, clonal myeloid overlap malignancy affecting hematopoietic stem cells, most frequently diagnosed in older adults It arises from ineffective erythropoiesis combined with dysplastic bone marrow proliferation Defining clinical and pathophysiologic features include sustained peripheral thrombocytosis alongside dyserythropoiesis characterized by pathol...
- nih.gov
Anemia in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) is a hematologic complication of a rare, clonal myeloid overlap malignancy affecting hematopoietic stem cells, most frequently diagnosed in older adults
- ashpublications.org
Anemia in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) is a hematologic complication of a rare, clonal myeloid overlap malignancy affecting hematopoietic stem cells, most frequently diagnosed in older adults
- pitt.edu
Defining clinical and pathophysiologic features include sustained peripheral thrombocytosis alongside dyserythropoiesis characterized by pathologic iron accumulation, where ring sideroblasts constitute at least 15% of erythroid precursors (or at least 5% in the presence of an SF3B1 mutation)
Personalize your experience
Follow Anemia in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.